NEW YORK (GenomeWeb) – Grail said today that it has begun a clinical trial, STRIVE, for its next-generation sequencing-based blood test for early-stage cancer detection. The firm will collaborate with the Mayo Clinic and Sutter Health to enroll up to 120,000 women at the time when they receive a mammogram. The goal will be to train and validate the test.
The STRIVE study will enroll women at the Mayo and throughout the Sutter Health system in Northern California.